Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Lennox Gastaut Syndrome × Clear all
NCT05364021 2024-11-08

PACIFIC

Longboard Pharmaceuticals

Phase 1/2 Completed
52 enrolled

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡